Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients....Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%....Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors.

This study (NCT01260181) was a phase II, non-randomized, open-label study to evaluate the anti-tumoral activity of erlotinib in patients with locally advanced or metastatic NSCLC with EGFR activating mutations….Median disease duration was 1 month (0–32 months) and histology for 96.7% of patients was adenocarcinoma....For exon 19 patients, the median PFS was 14.4 months (95% CI: 4.2–41.8) and for exon 21 9.8 months (95% CI: 3.8–13.5).